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are urgently needed since current treatments rarely lead to cure. a sustained antibody response against WHsAg in a subset of ani-
We evaluated whether the oral small molecule toll-like receptor
(TLR7) agonist GS-9620 could induce durable antiviral efﬁcacy in
woodchucks chronically infected with woodchuck hepatitis virus
(WHV), a hepadnavirus closely related to human hepatitis B virus
(HBV).
Methods: After evaluating the pharmacokinetics, pharmaco-
dynamics and tolerability of oral GS-9620 in uninfected wood-
chucks, adult woodchucks chronically infected with WHV (n = 7
per group) were dosed with GS-9620 or placebo for 4 or 8 weeks
with different treatment schedules.
Results: GS-9620 treatment induced rapid, marked and sustained
reduction in serum viral DNA (mean maximal 6.2 log10 reduc-
tion), and hepatic WHV DNA replicative intermediates, WHV
cccDNA and WHV RNA, as well as loss of detectable serumJournal of Hepatology 20
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QW, every week; QOW, every other week; M, module.mals. Strikingly, treatment reduced the incidence of hep-
atocellular carcinoma (HCC) from 71% in the placebo group to
8% in GS-9620-treated woodchucks with sustained viral load
reduction. GS-9620 treatment was associated with reversible
increases in serum liver enzymes and thrombocytopenia, and
induced intrahepatic CD8+ T cell, NK cell, B cell and interferon
response transcriptional signatures.
Conclusions: The data demonstrate that short duration, ﬁnite
treatment with the oral TLR7 agonist GS-9620 can induce a sus-
tained antiviral response in the woodchuck model of CHB, and
support investigation of this compound as a therapeutic approach
to attain a functional cure in CHB patients.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
An estimated 350 million people have chronic hepatitis B virus
infection (CHB), and over 500,000 people die each year due to
HBV-associated liver diseases, such as cirrhosis and hep-
atocellular carcinoma (HCC) [1]. Current therapeutics for CHB
are limited to nucleos(t)ides and interferon alpha (IFN-a); these
reduce viral load, improve long-term outcome, but rarely lead
to a cure [2]. Immunologic control of CHB, recognized as a ‘‘func-
tional cure,’’ is deﬁned by control of viremia, loss of HBV surface
antigenemia (HBsAg), and seroconversion to anti-HBs antibody
(HBsAb) and occurs in only 2–3% of patients per year with anti-
virals [2]. Functional cure with long-term IFN treatment occurs
in <10% of patients at doses associated with treatment-limiting
adverse effects [2]. There is therefore an urgent need for a cura-
tive therapy.
Natural infection with woodchuck hepatitis virus (WHV), a
hepadnavirus closely related to the HBV, occurs in the Eastern15 vol. 62 j 1237–1245
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woodchuck (Marmota monax). Chronic WHV infection is a model
for studying CHB, hepadnavirus-associated HCC, and is used to
evaluate HBV therapeutics [3]. Importantly, comparison of the
intrahepatic transcriptional proﬁles in woodchucks and humans
with chronic hepadnaviral infection identiﬁed important paral-
lels in the antiviral immune responses and demonstrated
molecular similarities in HCC induced by WHV and HBV [4]. As
this establishes the translational value of theWHVmodel, we uti-
lized it to explore therapeutic immunomodulation with the small
molecule TLR7 agonist GS-9620.
TLR7 is expressed predominantly in plasmacytoid dendritic
cells (pDCs) and B lymphocytes and recognizes viral single-
stranded RNA [5]. TLR7 activation induces innate and adaptive
immune responses via induction of speciﬁc cytokines (including
multiple IFN-a subtypes [6]) and chemokines, activation of B cells
[7], and cross-priming of cytotoxic lymphocytes [8]. GS-9620 is a
selective, oral small molecule TLR7 agonist that has activity in
rodents, nonhuman primates and humans [9–12]. A single dosing
regimen (three times a week for 8 weeks) of GS-9620 has pre-
viously been evaluated in a small number of chimpanzees
(n = 3) with CHB [10]. Here we report a placebo-controlled study
in which the activity of different regimens and treatment dura-
tions of GS-9620 were evaluated in woodchucks chronically
infected with WHV. Importantly, this model provided a unique
opportunity to evaluate the antiviral activity of GS-9620 in a
model of vertical transmission and to determine treatment
impact on development of hepadnavirus-associated HCC.Materials and methods
Investigational drug
GS-9620, (8-(3-(pyrrolidin-1-ylmethyl)benzyl)-4-amino-2-butoxy-7,8-dihydrop-
teridin-6(5H)-one), a small molecule, selective TLR7 agonist, was manufactured
by Gilead Sciences, Inc. [9]. Doses were administered in a liquid diet (1 mg/ml;
79002 Liquid Woodchuck Control Diet, Dyets, Inc., Bethlehem, PA) in a dose
volume of 10 ml. Placebo-treated woodchucks were administered liquid
diet alone.
Woodchuck TLR7 cloning and sequencing
Total RNA was isolated from woodchuck PBMC using RNeasy extraction kit
(QIAGEN, Redwood City, CA) and DNA was synthesized using SuperScript III
First-Strand Synthesis System (Life Technologies, Chicago, IL) according to the
manufacturer’s instructions. Woodchuck TLR7 (wTLR7) sequence was identiﬁed
by a PCR-based strategy using various primers that were designed based on
highly conserved sequences between human TLR7 (NM_016562.3) and mouse
TLR7 (NM_133211.3). The 50- and 30-ends of wTLR7 were identiﬁed using 50
and 30 RACE System kits respectively according to the manufacturer’s instructions
(Life Technologies, Chicago, IL). All ampliﬁed PCR fragments were sequenced to
obtain the complete wTLR7 sequence, deposited into NCBI (Accession TBD Prior
to Publication). wTLR7 was synthesized and cloned into pUNO1-hTLR7-HA3x vec-
tor (InvivoGen, San Diego, CA) in place of human TLR7 to generate pUNO1-
wTLR7-HA3x.
HEK293 TLR7 assay
Human embryonic kidney (HEK) 293 cells (CRL1573-ATCC) were seeded in 96
well plates in DMEM-GlutaMAX-I supplemented with 10% FBS. Eight hours post
seeding, the cells were co-transfected with either human TLR7 (pUNO1-hTLR7-
HA3x) or wTLR7 (pUNO1-wTLR7-HA3x) along with the NF-jB luciferase reporter
pNiFty2-Luc (InvivoGen, San Diego, CA) using TransIT-293 transfection reagent
(Mirus, Pittsburgh, PA) according to the manufacturer’s instructions. Eighteen
hours post-transfection the cells were stimulated with various concentrations1238 Journal of Hepatology 2015of GS-9620 for 6 h. Cells were lysed using ONE-Glo Luciferase assay system
(Promega, Madison, WI) and NF-jB luciferase activity measured using a VICTOR
X Light Luminescence plate reader (Perkin-Elmer, Waltham, MA).
Animals
Protocols were approved by the Institutional Animal Care and Use Committee of
Cornell University. Neonatal woodchucks were infected at 3 days of age with a
WHV7P1 inoculum containing 5  106 WID50 of WHV strain WHV7-11 and were
then raised to adulthood prior to use in this study. All infected woodchucks were
monitored serologically through 1 year post infection. At the start of the study all
woodchucks had antibody to WHV core antigen (anti-WHc antibody), were nega-
tive for antibody to WHV surface antigen (anti-WHs antibody; WHsAb), had
serum WHV DNA levels P109 ge/ml and detectable WHV surface antigen
(WHsAg) at pretreatment, and were free of HCC by ultrasound liver examination
and serum gamma glutamyl transferase (GGT). Uninfected control woodchucks
were negative for anti-WHc antibody, anti-WHs antibody, WHsAg, and WHV
DNA.Single dose pharmacokinetic (PK) and pharmacodynamic (PD) study in uninfected
woodchucks
Uninfected healthy, adult male woodchucks (n = 3 per dose group) were orally
administered 1, 5, or 10 mg/kg of GS-9620. Evaluations included clinical observa-
tions, clinical pathology, pharmacokinetics and pharmacodynamics. Serum levels
of GS-9620 were measured over time to calculate maximum serum concentration
(Cmax) and exposure, calculated as area under the serum concentration vs. time
curve (AUClast).
Efﬁcacy study in woodchucks chronically infected with WHV
The study design is described in Table 1. Brieﬂy, ﬁve groups of woodchucks (n = 7
per group, mixed sex) were treated with GS-9620 for approximately 4 weeks
(groups 1, 2, and 3) or 8 weeks (groups 4 and 5) and evaluations continued
through 35 weeks (time of scheduled euthanasia). Woodchucks that developed
HCC were euthanized; HCC was diagnosed by ultrasound and serum GGT and
conﬁrmed at necropsy. Woodchucks that died unexpectedly during the study
were evaluated by necropsy. Serum GS-9620 levels were evaluated at week 4,
4 h post-dose, the approximate time of peak exposure.
Determination of GS-9620 in serum
Woodchuck serum was mixed with acetonitrile containing an internal standard.
After protein precipitation and centrifugation, the supernatant was mixed with
water with 0.1% formic acid. An aliquot was injected to a TSQ Ultra Quantum
LC/MS/MS system (Thermo Finnigan, San Jose, CA).
Clinical pathology
Clinical pathology was assessed at pretreatment, approximately weekly during
treatment (24 h post-dose), at least 1 and 2 weeks after the last dose, and
approximately monthly through the end of the 35 week study [13].
WHV serum viremia levels
WHV DNA was quantiﬁed by two different methods depending on concentration:
dot blot hybridization or real-time PCR assay on a 7500 Real-Time PCR System
instrument (Applied Biosystems, Foster City, CA) as described previously [14].Hepatic levels of WHV nucleic acids
Liver levels of WHV DNA replicative intermediates (RI), WHV cccDNA, and WHV
RNA were determined in liver biopsies collected 2 weeks prior to treatment and
at selected time-points during and after treatment. Biopsies were obtained under
general anesthesia with a 16-gauge needle directed by ultrasound imaging.
Biopsy specimens for WHV nucleic acid analyses were placed immediately in
liquid nitrogen and stored at 70 C. WHV RNA was measured quantitatively
by Northern blot hybridization as previously described [15,16]. WHV DNA RIvol. 62 j 1237–1245
Table 1. Design of GS-9620 efﬁcacy study.
Group Animals(n = 7/group) Intended regimen
a Dose
(mg/kg)
1 WHV infected, placebo control QOD×4 weeks 0
2 Uninfected, GS-9620-treated QOD×4 weeks
5 (5 doses)
2.5 (9 doses)
3 QOD×4 weeks 5 (5 doses)2.5 (9 doses)
4 WHV infected, GS-9620-treated
QOD every other week 
(QOW) for 8 weeks
5 (4 doses)
2.5 (12 doses)
5 QW×8 every week for 8 weeks 5 (8 doses)
aQOD, every other day; QW, once a week; QOW, every other week.
JOURNAL OF HEPATOLOGYand WHV cccDNA was quantitatively determined by Southern blot hybridization
as previously described [17]. WHV cccDNA levels were expressed as a percentage
change from pretreatment level.
WHV serology
WHsAg and anti-WHs antibody were assessed approximately weekly through
week 10 and then monthly through week 35 using WHV-speciﬁc enzyme
immunoassays [18]. Serum WHsAg was quantiﬁed by ELISA against a standard
curve for puriﬁed WHsAg (lower sensitivity: ca. 30 ng/ml serum). Anti-WHsAb
titer was quantiﬁed by ELISA as described [18].
Statistical analyses for repeat-dose study
Analysis of variance (ANOVA) models using SAS PROC GLM were performed to
compare treatment effects of continuous PD response variables, serum and liver
viral load variables. ANOVA was also performed to relate binary endpoints, such
as HCC incidence with PD response and with serum and liver viral load variables.
Pearson correlation coefﬁcients, using SAS PROC CORR, were calculated for PD
response variables with viral load reduction, liver WHV DNA RI, RNA, and
cccDNA reduction.
Pharmacodynamic (PD) analyses
Methods for quantitative RT-PCR and RNA-Seq analysis are provided in the
Supplementary Materials.
RNA-Seq data archiving
The RNA-Seq data has been deposited in the NCBI GEO under accession number
GSE67935.Results
Single dose pharmacokinetics, pharmacodynamics and tolerability of
GS-9620 in uninfected adult woodchucks
After single oral doses of 1, 5 and 10 mg/kg, the average Cmax
of GS-9620 was 4.8 ± 1.4 nM, 23.6 ± 27.0 nM, and 660 ± 907 nM,
respectively, with an average Tmax at 3.7, 5.5, and 3.3 h, respec-
tively. GS-9620 exposure was roughly dose-proportional at 1
and 5 mg/kg but greater than proportional at 10 mg/kg
(Supplementary Fig. 2A). The pharmacodynamic (PD) response
was determined by measuring induction of mRNA levels of
the IFN-stimulated genes (ISGs) 2050-OAS and MxA in whole
blood (Supplementary Fig. 2B and C, respectively). ReagentsJournal of Hepatology 2015to measure woodchuck serum IFN-a protein were not available,
however 2050-OAS and MxA RNA levels are sensitive and estab-
lished markers of IFN-a induction in other species. In unin-
fected woodchucks, the average maximum fold increase from
pretreatment was 6.7, 11.8, and 11.0 for 2050-OAS after GS-
9620 doses of 1, 5 and 10 mg/kg, respectively, and 30.1, 35.6,
and 45.2, respectively, for MxA, with peak induction at 24 h
(Supplementary Fig. 2B and C). GS-9620 showed a similar dose
responsive induction of 2050-OAS and MxA in PBMCs across
other species, including cynomolgus monkeys, chimpanzees
and humans (Supplementary Table 1) [10–12]. GS-9620 has
comparable in vitro potency for woodchuck and human TLR7
(Supplementary Fig. 1).
GS-9620 induced transient increases in body temperature in
at least some woodchucks at each dose level (1, 5, and 10 mg/
kg). In addition, at the 5 and 10 mg/kg, GS-9620 induced tran-
sient hematological changes, including reversible decreases in
platelets (26% and 75% decrease at 5 and 10 mg/kg, respectively)
and lymphocytes (72% decrease at 10 mg/kg). Transient lympho-
cyte changes were consistent with trafﬁcking and/or margination
associated with TLR7 induced chemokines [19,20]. Based on
these single dose assessments, 5 mg/kg was chosen for the efﬁ-
cacy study.
GS-9620 efﬁcacy study in woodchucks chronically infected with
WHV
The efﬁcacy study evaluated adult woodchucks (12–14 months
of age) chronically infected with WHV. In order to model verti-
cal transmission in humans, chronic infection in these adult ani-
mals was established by neonatal WHV infection (see Materials
and methods). As described in Table 1, ﬁve groups of wood-
chucks (n = 7 per group, both males and females) were treated
with either GS-9620 (groups 2–5) or placebo (group 1).
Groups 3–5 comprised chronically infected animals treated with
GS-9620 at different schedules. Control groups included WHV-
infected animals treated with placebo (group 1), and uninfected
animals treated with GS-9620 (group 2). Due to thrombocytope-
nia noted during the ﬁrst 2 weeks of GS-9620 treatment in some
animals (data not shown), dosing was interrupted for 9 to
10 days for groups 2 and 3, and then reinitiated with dose
reduction to 2.5 mg/kg in groups 2, 3, and 4. Group 5, treated
weekly, was not dose reduced. No further changes in dose or
schedule occurred. Treatment duration was thus approximately
4 weeks (groups 1, 2, and 3) or 8 weeks (groups 4 and 5) and
evaluations continued through 35 weeks (time of scheduled
euthanasia).
The serum exposure of GS-9620 at 5 and 2.5 mg/kg
(Supplementary Table 2) was consistent with single dose data
in uninfected woodchucks (Supplementary Fig. 2A). GS-9620
administration induced statistically signiﬁcant (p <0.05)
increases in 2050-OAS and MxA RNA transcripts in all treated ani-
mals (Fig. 1; Supplementary Fig. 3) with the exception of four
WHV-infected animals in group 4 (QOD  8 weeks). Because of
these four non-responding animals, group 4 generally had lower
but still signiﬁcant (p <0.05) induction of 2050-OAS, but did not
have signiﬁcant induction of MxA. Induction of 2050-OAS and
MxA was statistically signiﬁcantly higher in GS-9620-treated
uninfected animals (group 2) vs. WHV-infected woodchucks
(groups 3, 4, and 5) (all p <0.05).vol. 62 j 1237–1245 1239
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Fig. 1. Pharmacodynamic response to GS-9620 administration. Mean fold
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5. Individual animal data is shown in Supplementary Fig. 8.
Research ArticleTolerability of GS-9620 treatment in woodchucks chronically
infected with WHV
The most common adverse effects were transient, dose-depen-
dent thrombocytopenia and increases in serum liver enzymes
(AST, ALT, GGT, and SDH). Reductions in platelets occurred pri-
marily at 5 mg/kg and, when present, recovered between weekly
treatments. Increases in serum liver enzymes occurred in all
study groups including placebo-treated WHV-infected wood-
chucks, but were more consistent in WHV-infected, GS-9620-
treated woodchucks (Fig. 2; Supplementary Fig. 8). The increases
in liver enzymes observed in placebo-treated, WHV-infected
woodchucks were likely related to WHV infection, as described
previously [21]. In GS-9620-treated, WHV-infected woodchucks,
transient serum liver enzyme increases generally occurred during
the treatment period and coincided with viral load reduction
(Fig. 2; Supplementary Fig. 8). Liver enzyme increases were likely
due to a combination of spontaneous increases associated with
WHV infection as noted in placebo-treated woodchucks (group
1), possible GS-9620 effects as observed in GS-9620-treated,
uninfected woodchucks (group 2), or hepatocellular effects
related to an antiviral immune response.
No deaths occurred in GS-9620-treated uninfected wood-
chucks (group 2) or in GS-9620-treated, WHV-infected wood-
chucks treated for approximately 4 weeks (group 3). Two
woodchucks in the placebo-treated WHV-infected group and
one GS-9620-treated WHV-infected animal in group 5 were
euthanized due to HCC. A non-treatment related death occurred
in group 5 from hemorrhage caused by a liver biopsy procedure.
Mortality or euthanasia occurred in two other WHV-infected
woodchucks treated with GS-9620 for 8 weeks, one at the end
of treatment (group 5) and one during the post-treatment evalua-
tion period (group 4). The former animal had microscopic ﬁnd-
ings consistent with a bacterial/viral infection that likely1240 Journal of Hepatology 2015contributed to the death. The other animal, based on its clinical
chemistries and liver pathology (chronic inﬂammation, necrosisvol. 62 j 1237–1245
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Journal of Hepatology 2015and nodular regeneration) had diminished liver function which
contributed to its poor clinical condition leading to euthanasia.
Because of the complex disease pathogenesis of chronic WHV
infection in woodchucks and inﬂammatory processes associated
with chronic infection, the role of GS-9620 treatment in these
two mortalities is undetermined.
Antiviral efﬁcacy of GS-9620 treatment in woodchucks chronically
infected with WHV
GS-9620 treatment induced marked, sustained reductions in
serum WHV DNA noted as early as the ﬁrst week of treatment.
GS-9620 induced reductions in viremia occurred in nearly all
GS-9620-treated woodchucks by week 4 (Fig. 3 and Table 2).
In contrast, the placebo group had no changes in serum WHV
DNA. WHV-infected woodchucks treated QOD for 4 weeks
(group 3) had a uniformly marked antiviral response with a
mean maximal viral load reduction of 6.2 log10. At the end of
the study (week 35), this group had a mean 4.8 log10 reduction
in viral load. Mean viral load in this group during weeks 3–35
were signiﬁcantly reduced compared to pretreatment (all
p <0.05) and the placebo control group at weeks 2–35 (all
p <0.05). Similar efﬁcacy occurred in animals that completed
weekly (QW) GS-9620 treatment for 8 weeks (group 5) (Fig. 3
and Table 2). In this group (group 5), GS-9620 treatment caused
statistically signiﬁcant reductions in viral load compared to pre-
treatment and the placebo control group at weeks 2–35 (all
p <0.05) with a mean maximal viral load reduction of 6.1 log10
and a sustained mean 5.0 log10 viral load reduction at the end
of the study (week 35). Strikingly, after completion of only 4
or 8 weeks of GS-9620 treatment, suppression of viral load
was sustained through the end of the study (week 35) in all
woodchucks in group 3 (QOD  4 weeks), and in 4 of 5 wood-
chucks in group 5 (QW  8 weeks) that completed treatment
(Fig. 3C and E).
In woodchucks treated QOD every other week (QOD QOW)
(group 4), three of seven animals had marked decreases in viral
load (Fig. 3D). Two of these three animals survived to week 35;
one maintained a 2 log10 decrease in viral load, whereas viremia
returned to pretreatment levels by week 18 in the other animal
(Fig. 3D). These three woodchucks had a PD response com-
parable to GS-9620-treated WHV-infected woodchucks in
groups 3 and 5, whereas the four woodchucks in this group that
did not have a reduction in viral load had a lower PD response
based on MxA and 2050-OAS RNA induction (Supplementary
Fig. 3D, I, and K). It is not clear why these four animals had
lower PD responses to GS-9620, although drug exposure
(Supplementary Table 2), animal gender and relative tumor bur-
den (Supplementary Fig. 8) do not appear to be contributing
factors.Fig. 3. Serum viral DNA levels in WHV-infected woodchucks. (A) Group
geometric means and (B–E) individual animal levels. Geometric means were
calculated from animals that completed treatment and had an antiviral response
to GS-9620 in the treatment groups (P1 log10 reduction in serum viral load at
more than one time point evaluated; Table 2). Group 2 animals were not infected
with WHV and were therefore not included in the plots. Tx: treatment.
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Table 2. Summary of efﬁcacy parameters and hepatocellular carcinoma (HCC) incidence in GS-9620-treated woodchucks.
Group Mean maximal viral load log 
reduction in animals with 
viral responsea
Number of animals HCC incidence
Sustained viral 
responseb
Loss of serum 
WHsAg
Anti-WHs 
antibody
All animals Animals with 
sustained response
1 n.a. 0/7 0/7 0/7 5/7 n.a.
2 n.a. n.a. n.a. n.a. n.a. n.a.
3 6.2 ± 1.1 (n = 7) 7/7 7/7 3/7 0/7 0/7
4 6.0 ± 0.8 (n = 3)c 1/3 2/3 1/3 0/3 0/1
5 6.1 ± 1.8 (n = 5)d 4/5 4/5 3/5 2/5 1/4
aAnimals with a viral response were deﬁned as any animal that hadP1 log10 reduction in serum viral load at more than one time point evaluated; data shown are from the
animals with a viral response that completed treatment (mortality occurred in two animals in group 5 during the treatment phase). The serum viral load was determined by
PCR and the limit of detection for the assay was 1  103 virus genome copies (vge)/ml [14].
bSustained viral response were deﬁned as a P2 log10 reduction in serum viral load at the end of study (week 35).
cThree group 4 animals (n = 7 total) were deﬁned as having a viral response to treatment.
dGroup 5 values were derived from the 5 of 7 animals that completed the 8 weeks of treatment.
0
500
1000
1500
2000
2500
Group 1: Placebo
Group 3: 5/2.5 mg/kg QOD
Group 4: 5/2.5 mg/kg QOD QW
Group 5: 5 mg/kg QW
p = 0.7141
A
p = 0.0008
p = 0.0013
eo
m
et
ric
 m
ea
n 
he
pa
tic
 W
H
V
N
A 
R
I (
pg
/µ
g 
ce
ll 
nu
cl
ei
c 
ac
id
)
Research ArticleGS-9620 treatment reduced the hepatic levels of WHV nucleic acids
Compared with placebo-treated woodchucks, levels of hep-
atic WHV DNA RI, WHV cccDNA, and WHV RNA were sig-
niﬁcantly (all p <0.005) decreased in groups 3 and 5 at
week 35, but not in group 4 (Fig. 4; Supplementary
Figs. 4–6). MxA and 2050-OAS RNA induction negatively cor-
related with the maximal reduction in serum WHV DNA,
liver WHV RI, and WHV cccDNA (all p <0.0001; r2 >0.55)
and positively correlated with liver WHV RNA (p <0.0001;
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GS-9620 treatment caused pronounced and sustained reduc-
tions in WHsAg (Fig. 5A and B, Supplementary Fig. 7).
Through week 35, GS-9620 treatment of group 3 woodchucks
(QOD  4 weeks) induced complete loss of detectable (<30 ng/
ml) WHsAg in all animals (7 of 7 woodchucks). Loss of detect-
able WHsAg also occurred in two of the three group 4 wood-
chucks (QOD  8 weeks) with a viral response to treatment,
and four of the ﬁve group 5 woodchucks (QW  8 weeks) that
completed treatment. Loss of detectable WHsAg occurred as
early as 2 weeks after the initiation of treatment. Mean
WHsAg was signiﬁcantly reduced in groups 3 and 5 at weeks
3–35 and weeks 2–35, respectively, when compared with the
pretreatment level (all p <0.05), and at weeks 1–35 and 2–35,
respectively, when compared with the placebo control (all
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Fig. 4. Intrahepatic levels of (A) WHV DNA replicative intermediates (RI), (B)
WHV cccDNA, and (C) WHV RNA in WHV-infected woodchucks. Geometric
means were calculated from animals that completed treatment and had an
antiviral response to GS-9620 in the treatment groups (P1 log10 reduction in
serum viral load at more than one time point evaluated; Table 2). Group 2
animals were not infected with WHV and were therefore not included in the
plots. The p values denote the level of statistical signiﬁcance at week 35 relative
to the placebo group.GS-9620 treatment induced anti-WHs antibody seroconversion in a
subset of animals
Seroconversion to WHsAb was observed in a subset of GS-9620-
treated woodchucks, but not in placebo-treated woodchucks
(Fig. 5C). Anti-WHsAb was detected in 3 of 7 woodchucks in
group 3, and 3 of 5 woodchucks in group 5. In these animals,
anti-WHsAb was ﬁrst noted as early as week 2, and as late as
week 21. Anti-WHsAb was also detected in 1 of the 3 wood-
chucks in group 4 that had viral load reduction in responses to
treatment. Anti-WHsAb titers in most woodchucks increased
gradually through week 35.1242 Journal of Hepatology 2015 vol. 62 j 1237–1245
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Fig. 5. Serum WHsAg and anti-WHs antibody levels in WHV-infected wood-
chucks. Geometric mean serumWHsAg in animals that (A) completed treatment,
and (B) had a sustained viral response. Sustained antiviral response was deﬁned
as P2 log10 reduction in viral load at week 35 (Table 2). Note that the animals
that were not sustained antiviral responders, also did not have a robust reduction
in serum WHsAg (Supplementary Fig. 8). Group 2 animals were not infected with
WHV and were therefore not included in the plots. (C) Seroconversion to anti-
WHs antibody in animals in groups 3, 4, and 5. Placebo-treated woodchucks had
no detectable antibody response.
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Fig. 6. Characterization of intrahepatic transcriptional signature associated
with GS-9620 treatment. Modular analysis of transcriptional signatures in the
liver of placebo-treated (group 1) and GS-9620-treated (group 5; 5 mg/kg QW)
animals relative to pretreatment (day 14). Columns represent different study
days. Spot intensity (red: over-expressed; blue: under-expressed) denotes the
percentage of transcripts signiﬁcantly changed in each module (M) and is deﬁned
by the scale bar. Only modules for which >15% of module genes were
differentially expressed (absolute fold-change >1.5 with a Benjamini-Hochberg
corrected FDR <0.05, and passed a low expression threshold) are displayed. The
functional interpretation of each module (taken from reference [23]) is displayed
on the right.
JOURNAL OF HEPATOLOGYGS-9620 treatment reduces the incidence of hepatocellular
carcinoma in woodchucks chronically infected with WHV
The incidence of HCC was markedly reduced in GS-9620-treated
woodchucks (Table 2). In placebo-treated WHV-infected wood-
chucks, HCC occurred in 5 of the 7 (71%) woodchucks, consistent
with the previous observation that nearly all chronic WHV car-
riers develop HCC over time [22]. In contrast, for all GS-9620-
treated woodchucks that completed treatment and had a viral
load reduction in response to treatment, the incidence was 2 of
15 (13%). Importantly, in GS-9620-treated woodchucks that had
a sustained reduction in viral load, the incidence of HCC was only
1 of 12 (8%) (Table 2).
Intrahepatic transcriptional response to GS-9620 treatment
As outlined in Supplementary Fig. 9, intrahepatic transcriptional
proﬁles of placebo-treated (group 1) and GS-9620-treated (group
5; 5 mg/kg QW) animals were determined by RNA-Seq at variousJournal of Hepatology 2015times during the study, and were characterized by a gene module
approach [23] and ingenuity pathway analysis (IPA). Modular
analysis (Fig. 6) revealed that GS-9620 treatment induced
cytotoxic cell (CD8+ T cell/NK cell) (Module, M2.1), T cell
(M2.8), myeloid cell lineage (M1.5 and M2.6), B cell (M1.3), and
IFN response (M3.1) intrahepatic transcriptional signatures. In
contrast, there was modest induction of only neutrophil (M2.2)
and IFN response (M3.1) gene signatures in the liver of pla-
cebo-treated animals (Fig. 6). The moderate intrahepatic induc-
tion of these two gene signatures was likely related to WHV
infection, as described previously [4]. The induction of intrahep-
atic CD8+ T, NK and B cell transcriptional signatures by GS-9620
treatment was conﬁrmed by IPA (Supplementary Fig. 10), and is
consistent with differential expression of T cell (CD3D and
CD8A), NK cell (NKG7) and B cell (CD79B) markers
(Supplementary Fig. 11). Taken together with the elevation in
liver enzymes associated with GS-9620 treatment (Fig. 2) and
the differential expression of perforin (PRF1) (Supplementary
Fig. 11), these data suggest that the antiviral response induced
by GS-9620 was likely mediated, at least in part, by the cytolyticvol. 62 j 1237–1245 1243
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activity of CD8+ T cells and/or NK cells. In addition, the intrahep-
atic induction of IFN-c-stimulated genes (CXCL9, ubiquitin D;
UBD) (Supplementary Fig. 11) as well as various IFN-a/b-stimu-
lated genes (M3.1, Fig. 6) [4], suggests that non-cytolytic mecha-
nisms may also play an important role in the antiviral response to
GS-9620 treatment.Discussion
Treatment of WHV-infected woodchucks with GS-9620 resulted
in rapid, marked and sustained antiviral response. GS-9620 phar-
macodynamic responses were consistent with activation of TLR7
and correlated statistically with antiviral efﬁcacy. Importantly,
the magnitude of ISG induction in chronically infected wood-
chucks was similar to that induced in humans at well tolerated
doses (Supplementary Table 1) [11]. Strikingly, in most chroni-
cally infected animals GS-9620 induced a multi-log reduction in
viral load, WHsAg loss and anti-WHs antibody seroconversion,
and reduced cccDNA levels and HCC incidence. Speciﬁcally,
reductions in viral load occurred in 15 of 19 woodchucks that
completed treatment (regardless of regimen) and viral load
reductions were sustained through the end of the study in 12
of these 15 woodchucks. Sustained WHsAg loss occurred in 13
of 15 woodchucks that completed treatment. Importantly, in 8
of 13 treated woodchucks with WHsAg loss, induction of
WHsAb occurred and persisted. In GS-9620-treated woodchucks
that had a sustained reduction in viral load, the incidence of
HCC was less than 10% compared to a rate of over 70% in the pla-
cebo group.
The antiviral responses induced by GS-9620 are clearly differ-
entiated from those observed with nucleos(t)ides evaluated in
the woodchuck model of CHB. While the duration of viral load
reduction was markedly longer with GS-9620 compared to simi-
lar treatment with nucleos(t)ides, the most important ﬁnding
was that, in contrast to GS-9620, nucleos(t)ide treatment induced
a sustained loss of WHsAg in only a small minority of WHV-in-
fected woodchucks and induction of anti-WHsAb was rare
[3,14]. Other therapeutic strategies in this model have included
therapeutic vaccination, IL-12 gene therapy and inhibition of
PD-L1 [24–26]. Although, in some instances, these therapies have
yielded transient reductions in viral load, WHsAg and induction
of anti-WHsAb, no single agent has been reported to induce a
comparable antiviral response to GS-9620. Most notably, while
treatment of chronically infected woodchucks with recombinant
woodchuck IFN-a strongly reduced serumWHV DNA and WHsAg
in some treated animals, this was a transient response that was
not accompanied by anti-WHsAb seroconversion in most wood-
chucks (Menne S, unpublished data).
Similar to a previous report in HBV-infected chimpanzees
[10], GS-9620 treatment in woodchucks was associated with
thrombocytopenia and liver enzyme increases. These adverse
effects were transient, reversed with dose holiday, had reduced
incidence and severity with lower doses, and were monitored
by routine clinical laboratory parameters. Increases in liver
enzymes were noted in some animals throughout all groups,
including placebo-treated animals, and were reversible in most
cases without dose reduction or treatment cessation. The mecha-
nism by which GS-9620 treatment caused platelet reductions in
woodchucks is not clear. However, recent reports show that
TLR7 is expressed in platelets, that TLR7 activation can induce a
reduction in platelet count with no inﬂuence on thrombotic1244 Journal of Hepatology 2015properties, and these effects enhanced host immune response
and survival to viral infection [27]. As elevations in liver enzymes
noted in GS-9620-treated animals were temporally associated
with reductions in hepatic cccDNA, liver enzyme increases may
represent immune-mediated killing of infected hepatocytes.
This is consistent with the induction of an intrahepatic cytotoxic
CD8+ T cell and/or NK cell transcriptional signature during GS-
9620 treatment. Notably, transient increases in liver enzymes
often precede clearance of acute hepadnavirus infection in wood-
chucks, chimpanzees and humans, and are thought to represent
development of effective intrahepatic antiviral immunity [28–
30].
The results demonstrate that short duration treatment with
GS-9620 can induce a durable therapeutic antiviral immune
response during chronic hepadnavirus infection. In a previous
study in chimpanzees chronically infected with HBV, GS-9620
treatment caused a sustained, albeit less marked reduction in
viral load and HBsAg [10]. While studies are ongoing to deﬁne
the cellular and molecular characteristics of the antiviral
response to GS-9620, it likely involves local induction of IFN-a,
as well as induction of antiviral NK and CD8+ T cell responses
[8,31,32]. In addition, direct activation of B cells by GS-9620
may also be an important mechanism that contributes to viral
clearance [33].
In summary, short duration treatment with GS-9620 induced
a sustained antiviral response and anti-WHs antibody serocon-
version in the woodchuck model of CHB. These data suggest that
GS-9620 may have the potential to therapeutically induce sus-
tained immunological control of chronic HBV infection in
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